Advertisement
UK markets closed

  • FTSE 100

    8,255.17
    -30.17 (-0.36%)
     

  • FTSE 250

    20,566.91
    -148.97 (-0.72%)
     

  • AIM

    793.48
    -3.06 (-0.38%)
     

  • GBP/EUR

    1.1772
    +0.0031 (+0.27%)
     

  • GBP/USD

    1.2721
    -0.0072 (-0.56%)
     

  • Bitcoin GBP

    55,757.65
    -426.46 (-0.76%)
     

  • CMC Crypto 200

    1,481.21
    +2.51 (+0.17%)
     

  • S&P 500

    5,357.13
    +4.17 (+0.08%)
     

  • DOW

    38,956.15
    +69.98 (+0.18%)
     

  • CRUDE OIL

    75.49
    -0.06 (-0.08%)
     

  • GOLD FUTURES

    2,325.90
    -65.00 (-2.72%)
     

  • NIKKEI 225

    38,683.93
    -19.58 (-0.05%)
     

  • HANG SENG

    18,366.95
    -109.85 (-0.59%)
     

  • DAX

    18,558.00
    -94.67 (-0.51%)
     

  • CAC 40

    8,006.40
    -33.72 (-0.42%)
     
REAL ESTATE:

10 bargain properties going under the hammer

Buying a home at auction can save you money, but preparation is key

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

XOMA Corporation
·1-min read
XOMA Corporation
XOMA Corporation

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET.  The presentation can be accessed at https://bit.ly/4aQ74Y8.

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

ADVERTISEMENT

About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

XOMA Investor Contact  

XOMA Media Contact

Juliane Snowden

Kathy Vincent

XOMA Corporation

KV Consulting & Management

+1 646-438-9754

+1 310-403-8951

juliane.snowden@xoma.com

kathy@kathyvincent.com